3B Blackbio DX Q4 FY24 earnings call: Revenue & Margins
Q4 FY24 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹23Cr
- +27.8% YoY
- +27.8% QoQ
- Net profit
- ₹9Cr
- +80% YoY
- 0% QoQ
- Margin
- 43%
- +2 pp YoY
- −7 pp QoQ
Guidance rank: #34 of 34 in Healthcare Services
See the sector's top 10 — free with your mobile number.
Based on 3B Blackbio DX Ltd's Q4 FY24 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q4 FY 2023-24 total revenue: INR 2,719.24 lakh vs. Quarterly EBITDA: INR 1,372.90 Lakh in Q4 FY 2023-24 vs.
From 3B Blackbio DX Ltd's Q4 FY24 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q4 FY 2023-24 total revenue: INR 2,719.24 lakh vs. INR 1,926.42 lakh in Q4 FY 2022-23 (approx. 41% increase).
- Q4 FY 2023-24 molecular diagnostic kits export sales: INR 290.15 lakh vs. INR 188.33 lakh in Q4 FY 2022-23 (~54% increase).
- Effective growth in Non-COVID Sales for Q4 FY 2023-24 approx. 20%, in line with expectations.
- Diagnostics business (3B Standalone Non-COVID) Q4 Sales: INR 1,721.40 lakh vs. INR 1,433.41 lakh in Q4 FY 2022-23 (~20% growth).
- Export business (non-COVID) increased by over 25% from previous fiscal, projecting 20-25% growth for next year.
- TRUPCR Europe Limited, Manchester site expected 40-50% growth next fiscal year.
2 more points from 3B Blackbio DX Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what 3B Blackbio DX Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company is continuously investing in additional manufacturing and R&D facilities to support existing business verticals (Page 34).
- Expansion efforts include enhancing operations at the UK subsidiary, TRUPCR® Europe Limited in Manchester, with a projected growth rate of 40%-50% next fiscal year (Page 24).
- Funds will be deployed in a joint venture in Manchester, UK, dependent on need (Page 34).
- The company is exploring acquisitions for inorganic growth since FY22 but will proceed only if financially sensible; if not, a share buyback is planned (Page 34).
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what 3B Blackbio DX Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
3B Blackbio DX Ltd — Quarterly revenue & net profit
3B Blackbio DX Ltd Q4 FY24 results — key figures
| ₹ Cr | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue | 23 | 18 | +27.8% | 18 | +27.8% |
| Operating profit (EBITDA) | 10 | 7 | +42.9% | 9 | +11.1% |
| Operating margin | 43% | 41% | +2 pp | 50% | -7 pp |
| Profit before tax | 14 | 8 | +75% | 11 | +27.3% |
| Net profit (PAT) | 9 | 5 | +80% | 9 | 0% |
| EPS (₹) | 10.33 | 7.72 | +33.8% | 10.16 | +1.7% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q3 FY26): revenue ₹50 Cr, net profit ₹22 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What 3B Blackbio's management said in earlier quarters
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- IndegeneGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
3B Blackbio DX Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were 3B Blackbio DX Ltd Q4 FY24 results?
Q4 FY 2023-24 total revenue: INR 2,719.24 lakh vs. Quarterly EBITDA: INR 1,372.90 Lakh in Q4 FY 2023-24 vs.
What is 3B Blackbio DX Ltd share price analysis?
3B Blackbio DX Ltd currently shows a neutral. The stock trades at a P/E of 20.4 with a market cap of ₹1,132 Cr. Investors should review the full earnings analysis for detailed insights.
Is 3B Blackbio DX Ltd planning capital expenditure?
The company is continuously investing in additional manufacturing and R&D facilities to support existing business verticals (Page 34).
Keep 3B Blackbio DX Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
